Genomic medicine: Genetic variation and its impact on the future of health care

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 360, Issue 1460, 2005, Pages 1543-1550

  Willard, Huntington F ^a   Angrist, Misha ^a   Ginsburg, Geoffrey S ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Gene expression profiling; Genomic medicine; Metabolomics; Microarrays; Personalized health care; Proteomics

Indexed keywords

CANCER; GENETIC VARIATION; HEALTH CARE;

ENGLAND; EURASIA; EUROPE; LONDON [ENGLAND]; UNITED KINGDOM; WESTERN EUROPE;

ECONOMICS; ETHICS; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; GENETICS; GENOMICS; HEALTH CARE DELIVERY; MEDICAL GENETICS; METHODOLOGY; NEOPLASM; REVIEW;

DELIVERY OF HEALTH CARE; GENE EXPRESSION PROFILING; GENETICS, MEDICAL; GENOMICS; NEOPLASMS; VARIATION (GENETICS);

EID: 27444434741     PISSN: 09628436     EISSN: None     Source Type: Journal    
DOI: 10.1098/rstb.2005.1683     Document Type: Conference Paper

References (78)

1. Abbate, A., Biondi-Zoccai, G. G., Brugaletta, S., Liuzzo, G. & Biasucci, L. M. 2003 C-reactive protein and other inflammatory biomarkers as predictors of outcome following acute coronary syndromes. Semin. Vasc. Med. 3, 375-384.
2. Adams, A. 2003 Metabolomics: small-molecule 'omics. Scientist 17, 38-40.
3. Ahmadi, K. R. et al. 2005 A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nature Genet. 37, 84-89.
4. Altshuler, D. & Clark, A. G. 2005 Harvesting medical information from the human family tree. Science 18, 1052-1053.
5. Angell, M. 2004 Excess in the pharmaceutical industry. Can. Med. Assoc. J. 171, 1451-1453.
6. Arita, M. 2004 Additional paper: computational resources for metabolomics. Brief. Funct. Genomic Proteomic 3, 84-93.
7. Bentley, D. R. 2004 Genomes for medicine. Nature 429, 440-445.
8. Bukowska, A., Lendeckel, U., Kahne, T. & Goette, A. 2004 Proteomics in myocardial diseases. Pathol. Res. Pract. 200, 135-145.
9. Bundorf, M. K., Singer, S. J., Wagner, T. H. & Baker, L. 2004 Consumers' use of the Internet for health insurance. Am. J. Manag. Care 10, 609-616.
10. Bundy, J. G., Willey, T. L., Castell, R. S., Ellar, D. J. & Brindle, K. M. 2005 Discrimination of pathogenic clinical isolates and laboratory strains of Bacillus cereus by NMR-based metabolomic profiling. FEMS Microbiol. Lett. 242, 127-136.
11. Burns, M. A., He, W., Wu, C. L. & Cheng, L. L. 2004 Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics. Technol. Cancer Res. Treat. 3, 591-598.
12. Cara, C. J., Pena, A. S., Sans, M., Rodrigo, L., Guerrero-Esteo, M., Hinojosa, J., Garcia-Paredes, J. & Guijarro, L. G. 2004 Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med. Sci. Monit. 10, RA247-RA254.
13. Chung, C. H., Bernard, P. S. & Perou, C. M. 2002 Molecular portraits and the family tree of cancer. Nature Genet. 32(Suppl.), 533-540.
14. Collie-Duguid, E. S., Pritchard, S. C., Powrie, R. H., Sludden, J., Collier, D. A., Li, T. & McLeod, H. L. 1999 The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 9, 37-42.
15. de Hoog, C. L. & Mann, M. 2004 Proteomics. Annu. Rev. Genomics Hum. Genet. 5, 267-293.
16. de Lemos, J. A. & Morrow, D. A. 2003 Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. Rev. Cardiovasc. Med. 4(Suppl. 4), S37-S46.
17. Diamandis, E. P. 2004 Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl Cancer Inst. 96, 353-356.
18. Emonts, M., Hazelzet, J. A., de Groot, R. & Hermans, P. W. 2003 Host genetic determinants of Neisseria meningitidis infections. Lancet Infect. Dis. 3, 565-577.
19. Garber, K. 2004 Debate rages over proteomic patterns. J. Natl Cancer Inst. 96, 816-818.
20. Garcia-Barcelo, M. et al. 2005 TTF-1 and RET promoter SNPs: regulation of RET transcription in Hirschsprung's disease. Hum. Mol. Genet. 14, 191-204.
21. Ginsburg, G. S. & McCarthy, J. J. 2001 Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol. 19, 491-496.
22. Glinsky, G. V., Higashiyama, T. & Glinskii, A. B. 2004 Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm. Clin. Cancer Res. 10, 2272-2283.
23. Goff, V. 2004 Consumer cost sharing in private health insurance: on the threshold of change. Issue Brief Natl Health Policy Forum, 1-19.
24. Goldstein, D. B., Tate, S. K. & Sisodiya, S. M. 2003 Pharmacogenetics goes genomic. Nat. Rev. Genet. 4, 937-947.
25. Guttman, A., Varoglu, M. & Khandurina, J. 2004 Multidimensional separations in the pharmaceutical arena. Drug Discov. Today 9, 136-144.
26. Hamilton, D. P. 2004 Genomic tests are predicting cancers' course. Wall St. J., B1.
27. Harrison, P. M., Kumar, A., Lang, N., Snyder, M. & Gerstein, M. 2002 A question of size: the eukaryotic proteome and the problems in defining it. Nucleic Acids Res. 30, 1083-1090.
28. Hawn, T. R., Verbon, A., Janer, M., Zhao, L. P., Beutler, B. & Aderem, A. 2005 Toll-like receptor 4 polymorphisms are associated with resistance to Legionnaires' disease. Proc. Natl Acad. Sci. USA 102, 2487-2489.
29. Herzlinger, R. E. 2002 Let's put consumers in charge of health care. Harv. Bus. Rev. 80, 44-50 see also p. 123
30. Higashi, M. K. & Veenstra, D. L. 2003 Managed care in the genomics era: assessing the cost effectiveness of genetic tests. Am. J. Manag. Care 9, 493-500.
31. Hinds, D. A., Stuve, L. L., Nilsen, G. B., Halperin, E., Eskin, E., Ballinger, D. G., Frazer, K. A. & Cox, D. R. 2005 Whole-genome patterns of common DNA variation in three human populations. Science 307, 1072-1079.
32. Hood, L. 2003 Systems biology: integrating technology, biology, and computation. Mech. Ageing Dev. 124, 9-16.
33. Imahara, S. D. & O'Keefe, G. E. 2004 Genetic determinants of the inflammatory response. Curr. Opin. Crit. Care 10, 318-324.
34. Ishikawa, T., Onishi, Y., Hirano, H., Oosumi, K., Nagakura, M. & Tarui, S. 2004 Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/ MDR1). Biol. Pharm. Bull. 27, 939-948.
35. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J. & Thun, M. J. 2005 Cancer statistics, 2005. CA Cancer J. Clin. 55, 10-30.
36. Kenna, G. A., McGeary, J. E. & Swift, R. M. 2004 Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1. Am. J. Health Syst. Pharm. 61, 2272-2279.
37. Khidekel, N. & Hsieh-Wilson, L. C. 2004 A 'molecular switchboard' - covalent modifications to proteins and their impact on transcription. Org. Biomol. Chem. 2, 1-7.
38. Kullo, I. J. & Ballantyne, C. M. 2005 Conditional risk factors for atherosclerosis. Mayo Clin. Proc. 80, 219-230.
39. Lander, E. S. et al. 2001 Initial sequencing and analysis of the human genome. Nature 409, 860-921.
40. Lazarou, J., Pomeranz, B. H. & Corey, P. N. 1998 Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J. Am. Med. Assoc. 279, 1200-1205.
41. Liljedahl, U., Kahan, T., Malmqvist, K., Melhus, H., Syvanen, A. C., Lind, L. & Kurland, L. 2004 Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment. J. Hypertens. 22, 2321-2328.
42. Liotta, L. A., Kohn, E. C. & Petricoin, E. F. 2001 Clinical proteomics: personalized molecular medicine. J. Am. Med. Assoc. 286, 2211-2214.
43. Loscalzo, J. 2003 Proteomics in cardiovascular biology and medicine. Circulation 108, 380-383.
44. Mariadason, J. M., Augenlicht, L. H. & Arango, D. 2003 Microarray analysis in the clinical management of cancer. Hematol. Oncol. Clin. North Am. 17, 377-387.
45. Masood, S. 2000 Assessment of prognostic factors in breast fine-needle aspirates. Am. J. Clin. Pathol. 113, S84-S96.
46. Maxwell, S. R. & Webb, D. J. 2005 COX-2 selective inhibitors - important lessons learned. Lancet 365, 449-451.
47. Meyer, J. M. & Ginsburg, G. S. 2002 The path to personalized medicine. Curr. Opin. Chem. Biol. 6, 434-438.
48. Morel, N. M., Holland, J. M., van der Greef, J., Marple, E. W., Clish, C., Loscalzo, J. & Naylor, S. 2004 Primer on medical genomics. Part XIV: introduction to systems biology - a new approach to understanding disease and treatment. Mayo Clin. Proc. 79, 651-658.
49. Narod, S. A. & Foulkes, W. D. 1994 BRCA1 and BRCA2: 1994 and beyond. Nature Rev. Cancer 4, 665-676.
50. Nevins, J. R., Huang, E. S., Dressman, H., Pittman, J., Huang, A. T. & West, M. 2003 Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum. Mol. Genet. 12, R153-R157.
51. O'Connor, A. M. et al. 2003 Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst. Rev., CD001431.
52. Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R. & O'Brien, C. P. 2003 A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28, 1546-1552.
53. Petricoin, E. F. et al. 2002 Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577.
54. Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K. & Breckenridge, A. M. 2004 Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br. Med. J. 329, 15-19.
55. Pittman, J. et al. 2004 Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc. Natl Acad. Sci. USA 101, 8431-8436.
56. Ransohoff, D. F. 2005 Lessons from controversy: ovarian cancer screening and serum proteomics. J. Natl Cancer Inst. 97, 315-319.
57. Rees-Unwin, K. S., Morgan, G. J. & Davies, F. E. 2004 Proteomics and the haematologist. Clin. Lab Haematol. 26, 77-86.
58. Reinhardt, U. E., Hussey, P. S. & Anderson, G. F. 2004 U.S. health care spending in an international context. Health Affair (Millwood) 23, 10-25.
59. Sakaeda, T., Nakamura, T. & Okumura, K. 2004 Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr. Top. Med. Chem. 4, 1385-1398.
60. Schmidt, C. W. 2004 Metabolomics: what's happening downstream of DNA. Environ. Health Perspect. 112, A410-A415.
61. Schnitt, S. J. 2001 Traditional and newer pathologic factors. J. Natl Cancer Inst. Monogr., 22-26.
62. Seibert, V., Wiesner, A., Buschmann, T. & Meuer, J. 2004 Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF-MS) and ProteinChip technology in proteomics research. Pathol. Res. Pract. 200, 83-94.
63. Shastry, B. S. 2002 SNP alleles in human disease and evolution. J. Hum. Genet. 47, 561-566.
64. Snyderman, R. & Williams, R. S. 2003 Prospective medicine: the next health care transformation. Acad. Med. 78, 1079-1084.
65. Tate, S. K. & Goldstein, D. B. 2004 Will tomorrow's medicines work for everyone? Nature Genet. 36, S34-S42.
66. Thrall, J. H. 2004 Personalized medicine. Radiology 231, 613-616.
67. Twyman, R. M. 2004 SNP discovery and typing technologies for pharmacogenomics. Curr. Top. Med. Chem. 4, 1423-1431.
68. Van Scoik, K. G., Johnson, C. A. & Porter, W. R. 1985 The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine. Drug Metab. Rev. 16, 157-174.
69. van 't Veer, L. J. et al. 2002 Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536.
70. Venter, J. C. et al. 2001 The sequence of the human genome. Science 291, 1304-1351.
71. Watkins, S. M. & German, J. B. 2002 Toward the implementation of metabolomic assessments of human health and nutrition. Curr. Opin. Biotechnol. 13, 512-516.
72. Weinshilboum, R. 2001 Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab. Dispos. 29, 601-605.
73. Weinshilboum, R. 2003 Inheritance and drug response. N. Engl. J. Med. 348, 529-537.
74. Weston, A. D. & Hood, L. 2004 Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J. Proteome Res. 3, 179-196.
75. Wheeler, D. L. et al. 2005 Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 33(Database Issue), D39-D45.
76. Williams, D. 2004 The critical path to medical innovation. Med. Device Technol. 15, 8-10.
77. Worthington, J. & John, S. 2003 Association of PADI4 and rheumatoid arthritis: a successful multidisciplinary approach. Trends Mol. Med. 9, 405-407.
78. Wulfkuhle, J., Espina, V., Liotta, L. & Petricoin, E. 2004 Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur. J. Cancer 40, 2623-2632.